

Michelle A Rudek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/353997/publications.pdf>

Version: 2024-02-01

63
papers

2,607
citations

270111

25
h-index

223390

49
g-index

66
all docs

66
docs citations

66
times ranked

5827
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of a rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of vistusertib. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 208, 114436.	1.4	1
2	Quantitation of terameprocol in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 209, 114525.	1.4	0
3	Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study. <i>Oncologist</i> , 2022, 27, 623-e624.	1.9	2
4	Exosome-Encased Nucleic Acid Scaffold Chemotherapeutic Agents for Superior Anti-Tumor and Anti-Angiogenesis Activity. <i>ACS Bio & Med Chem Au</i> , 2022, 2, 140-149.	1.7	4
5	HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	44
6	Serum Concentrations of Losartan Metabolites Correlate With Improved Physical Function in a Pilot Study of Prefrail Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 2356-2366.	1.7	3
7	Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. <i>European Radiology</i> , 2021, 31, 3002-3014.	2.3	10
8	Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma. <i>Annals of Surgery</i> , 2021, 273, e206-e213.	2.1	14
9	Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. <i>Blood Advances</i> , 2021, 5, 711-724.	2.5	10
10	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). <i>Clinical Cancer Research</i> , 2021, 27, 5828-5837.	3.2	18
11	High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review. <i>Cancer Treatment Reviews</i> , 2021, 97, 102171.	3.4	8
12	Clonidine for sedation in infants during therapeutic hypothermia with neonatal encephalopathy: pilot study. <i>Journal of Perinatology</i> , 2021, , .	0.9	3
13	Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa154.	0.4	13
14	Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclax. <i>Biomedical Chromatography</i> , 2021, , e5289.	0.8	1
15	A Novel 2-Carbon-Linked Dimeric Artemisinin With Potent Antileukemic Activity and Favorable Pharmacology. <i>Frontiers in Oncology</i> , 2021, 11, 790037.	1.3	5
16	A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 300-306.	2.0	36
17	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2020, 26, 5329-5337.	3.2	6
18	Successful gene therapy requires targeting the vast majority of cancer cells. <i>Cancer Biology and Therapy</i> , 2020, 21, 946-953.	1.5	1

#	ARTICLE	IF	CITATIONS
19	A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020, 13, 1178-1188.	1.5	23
20	Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids. <i>Leukemia</i> , 2020, 34, 3077-3081.	3.3	14
21	For HIPEC, synergistic effects of hyperthermia and doxorubicin are optimal when simultaneously combined. <i>International Journal of Hyperthermia</i> , 2020, 37, 346-348.	1.1	0
22	Increased uptake of doxorubicin by cells undergoing heat stress does not explain its synergistic cytotoxicity with hyperthermia. <i>International Journal of Hyperthermia</i> , 2019, 36, 711-719.	1.1	20
23	A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 5475-5484.	3.2	17
24	A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. <i>Cancer</i> , 2019, 125, 2837-2845.	2.0	17
25	Safety and Preliminary Efficacy of Vorinostat With EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 180-190.e2.	0.2	11
26	Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. <i>Nature Communications</i> , 2018, 9, 53.	5.8	175
27	Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma. <i>Aids</i> , 2018, 32, 605-611.	1.0	24
28	Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship. <i>Clinical and Translational Science</i> , 2018, 11, 435-443.	1.5	15
29	Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMCO34. <i>Leukemia and Lymphoma</i> , 2018, 59, 1851-1860.	0.6	21
30	The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. <i>Science Signaling</i> , 2018, 11, .	1.6	51
31	Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006728.	1.3	26
32	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. <i>Oncologist</i> , 2017, 22, 505-e49.	1.9	20
33	Entinostat: a promising treatment option for patients with advanced breast cancer. <i>Future Oncology</i> , 2017, 13, 1137-1148.	1.1	94
34	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacytidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. <i>Clinical Cancer Research</i> , 2017, 23, 2691-2701.	3.2	106
35	Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies. <i>Cancer Research</i> , 2017, 77, 5554-5563.	0.4	36
36	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 697-706.	3.2	56

#	ARTICLE	IF	CITATIONS
37	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. <i>Oncotarget</i> , 2017, 8, 104182-104192.	0.8	20
38	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology's Friends of Cancer Research HIV Working Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 3774-3780.	0.8	114
39	The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects. <i>Clinical Cancer Research</i> , 2016, 22, 5472-5479.	3.2	23
40	Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics. <i>NeuroMolecular Medicine</i> , 2016, 18, 581-592.	1.8	40
41	Ezrin Inhibition Up-regulates Stress Response Gene Expression. <i>Journal of Biological Chemistry</i> , 2016, 291, 13257-13270.	1.6	40
42	Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1022, 38-45.	1.2	11
43	The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. <i>Journal of Neuro-Oncology</i> , 2016, 126, 433-439.	1.4	41
44	A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 53, 54-59.	0.8	10
45	Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted <i>in vivo</i> , and synergized with antileukemic drugs. <i>Oncotarget</i> , 2016, 7, 7268-7279.	0.8	28
46	Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. <i>EMBO Molecular Medicine</i> , 2015, 7, 648-669.	3.3	189
47	A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. <i>Prostate</i> , 2015, 75, 1518-1525.	1.2	88
48	Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. <i>Clinical Cancer Research</i> , 2015, 21, 3462-3470.	3.2	66
49	Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma. <i>Neuro-Oncology</i> , 2015, 17, 70-80.	0.6	42
50	A phase I/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. <i>Cancer</i> , 2014, 120, 1194-1202.	2.0	26
51	A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity. <i>Cancer Cell</i> , 2014, 25, 77-90.	7.7	231
52	Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2042-2048.	2.0	219
53	Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2013, 19, 3631-3639.	3.2	59
54	Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432. <i>Clinical Cancer Research</i> , 2012, 18, 2954-2963.	3.2	68

#	ARTICLE	IF	CITATIONS
55	Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. <i>Investigational New Drugs</i> , 2012, 30, 2096-2102.	1.2	42
56	Use of antineoplastic agents in patients with cancer who have HIV/AIDS. <i>Lancet Oncology</i> , The, 2011, 12, 905-912.	5.1	137
57	Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 105, 375-381.	1.4	18
58	Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3033-3038.	1.2	46
59	A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 43, 784-787.	1.4	14
60	A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 37, 751-756.	1.4	4
61	Pharmacokinetics of 5-Azacididine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 3906-3911.	0.8	98
62	Temozolomide in Patients with Advanced Cancer: Phase I and Pharmacokinetic Study. <i>Pharmacotherapy</i> , 2004, 24, 16-25.	1.2	25
63	A method for determination of dimethyl benzoylphenyl urea(BPU) in human plasma by using LC/UV. <i>Biomedical Chromatography</i> , 2004, 18, 282-287.	0.8	3